MOTIVATION LETTER Heavy menstrual bleeding affects one in four women of reproductive age, yet in Nigeria the condition is routinely normalized, under-diagnosed, and untreated until it becomes an emergency. The clinical definition is precise: excessive menstrual blood loss that interferes with physical, social, emotional, and material quality of life. The diagnostic reality in low-resource settings is that most women never receive a measurement, a hemoglobin check, or a structured clinical assessment. Grand Challenges Africa has funded innovations that close exactly this kind of gap, and the Accelerating Innovations to Address Heavy Menstrual Bleeding programme is the right vehicle for a pharmacist-led digital screening pathway I have been building in Nigeria. I am a licensed pharmacist with a B.Pharm from the University of Ibadan and an incoming M.Sc. student in Digital Health at the Hasso Plattner Institute in Potsdam. I have spent the last two years building computational infrastructure for health applications, including four independent data pipelines and a self-hosted LLM serving stack. My current employment as National Product Manager at Synthcare, a Nigerian e-pharmacy platform, has shown me the exact point where digital health tools meet pharmacy practice in low-resource settings. Pharmacists are the first and often only health professional a Nigerian woman sees for menstrual complaints. They are not equipped with structured screening tools, and they have no referral pathway that connects abnormal bleeding to diagnostic confirmation and treatment. The innovation I propose is a pharmacist-administered HMB screening and referral application built on the Synthcare platform. The app will administer a validated structured questionnaire aligned with the NICE and FIGO definitions of HMB, capture menstrual history, calculate a pictorial blood loss assessment chart score, and flag hemoglobin risk using a low-cost color-based anemia screening protocol. The output is a triage classification: routine, needs laboratory confirmation, or urgent referral. The app generates a structured referral note for the nearest facility and logs the outcome for follow-up. This is a decision-support and referral tool that operates within the existing pharmacy network, requires no additional hardware, and costs less than two US dollars per screening episode. The programme's selection criteria emphasize innovations that are easy to use, affordable, and targeted at Sub-Saharan Africa. My proposal meets all three. The technology is a smartphone application with a simple interface designed for community pharmacists. The target population is Nigerian women aged 15 to 49 who currently have no structured pathway for HMB assessment. The budget is commensurate with a two-year, single-country implementation study. I am applying as an independent researcher with a Nigerian institution as the implementation site, which aligns with the programme's encouragement of LMIC-led applications. The study design is a prospective implementation trial across 40 community pharmacies in Oyo and Lagos States. Primary outcomes are screening uptake, referral completion rate, and time from screening to confirmed diagnosis. Secondary outcomes include the proportion of women with confirmed HMB who initiate treatment, and the positive predictive value of the pharmacist-administered screening tool against clinical diagnosis. The study will enroll 2,000 women over 18 months. The data will be published openly, and the tool will be released under a non-restrictive license so other LMIC pharmacy networks can adopt it. This proposal is grounded in my existing infrastructure. The Synthcare platform already serves Nigerian patients through a pharmacist-led model. The screening module is an extension of that platform, not a new venture. I am not claiming validated product-market fit or revenue from this module; it does not exist yet. What exists is the platform, the pharmacist network, the regulatory understanding, and the technical capacity to build and evaluate the tool rigorously. The programme's emphasis on original research and development matches my track record of pre-registered, openly reported studies, including a cardiotoxicity replication that settled a question the literature had never actually tested. Heavy menstrual bleeding is a treatable condition. The gap is not biomedical knowledge. The gap is a delivery mechanism that meets women where they already seek care. Nigerian pharmacists are that mechanism. This programme can fund the evidence that makes the mechanism work. RESEARCH STATEMENT The proposed research addresses the Innovative Diagnostics priority area of the Accelerating Innovations to Address Heavy Menstrual Bleeding programme. The central hypothesis is that a pharmacist-administered, smartphone-based screening and referral tool can identify women with clinically significant HMB in Nigerian community pharmacies with acceptable sensitivity and specificity, and can increase the proportion of affected women who reach confirmed diagnosis and treatment within 90 days. Background. HMB is defined as excessive menstrual blood loss that interferes with quality of life. In Nigeria, prevalence estimates range from 18 to 34 percent depending on the population and measurement method, but most affected women never receive a formal assessment. Community pharmacies are the first point of contact for many of these women. Pharmacists can dispense over-the-counter analgesics and hemostatic agents, but they lack a structured tool to distinguish normal variation from clinically significant bleeding, and they have no standardized referral pathway. The result is delayed diagnosis of underlying causes including fibroids, adenomyosis, and coagulopathies, with attendant anemia and reduced quality of life. Innovation. The proposed tool is a pharmacist-administered screening application deployed on the existing Synthcare e-pharmacy platform. The application has three components. First, a structured clinical questionnaire based on the NICE HMB guideline and the FIGO PALM-COEIN classification system, administered by the pharmacist in English or Yoruba. Second, a pictorial blood loss assessment chart score calculated from patient-reported pad and clot counts over the most recent menstrual period. Third, a hemoglobin risk flag using the WHO color scale method, a validated low-cost anemia screening approach that requires a single drop of blood and a printed color chart. The application combines these inputs into a triage classification with three outputs: routine advice and follow-up, laboratory confirmation recommended, or urgent referral. Each output generates a structured referral note and a follow-up reminder. Study design. The study is a prospective, multi-site implementation trial in 40 community pharmacies across Oyo and Lagos States. Pharmacies will be recruited from the Synthcare partner network and stratified by urban versus peri-urban location. Each pharmacy will screen consecutive eligible women aged 15 to 49 who present with a menstrual complaint or request for menstrual-related medication. Exclusion criteria are known pregnancy, current use of hormonal contraception, and known bleeding disorder. The target enrollment is 2,000 women over 18 months. Primary outcomes. The first primary outcome is the sensitivity and specificity of the pharmacist-administered screening tool against a reference standard of clinical diagnosis by a gynecologist, defined as a pictorial blood loss assessment chart score above 100 or clinically significant anemia with menstrual complaint. The second primary outcome is the referral completion rate, defined as the proportion of women flagged for laboratory confirmation or urgent referral who attend a follow-up appointment within 90 days. Secondary outcomes. Secondary outcomes include the proportion of women with confirmed HMB who initiate treatment within 90 days, the median time from screening to confirmed diagnosis, the positive predictive value of the tool, and the cost per screening episode. Cost data will include pharmacist time, materials, and data transmission, and will be reported in US dollars and Nigerian naira. Sample size and analysis. Based on a conservative sensitivity estimate of 80 percent with a precision of plus or minus 5 percent, a sample of 246 women with confirmed HMB is required. Assuming a 25 percent prevalence of HMB among women presenting with menstrual complaints, the total screening sample of 2,000 women provides adequate power. Analysis will use logistic regression for sensitivity and specificity with bootstrap confidence intervals, and time-to-event analysis for referral completion. All analysis code and de-identified data will be published on Zenodo. Ethics and regulatory compliance. The study will receive ethics approval from the University of Ibadan Research Ethics Committee and the Oyo State Ministry of Health Ethics Committee. The tool is a decision-support application, not a medical device, and does not require NAFDAC registration. Pharmacist training will be delivered through a two-day workshop covering HMB recognition, the screening protocol, and referral procedures. All participants will provide written informed consent. Budget and timeline. The total budget request is 120,000 US dollars over 24 months. Major line items are personnel for a research coordinator and two field supervisors, pharmacist training and incentives, data collection and server costs, and publication fees. The first six months cover ethics approval, tool development, and pharmacist training. Months 7 through 22 cover enrollment and follow-up. Months 23 and 24 cover analysis, manuscript preparation, and dissemination. The budget is within the programme's 150,000 dollar ceiling and the 15 percent indirect cost cap. Dissemination. Results will be reported regardless of outcome. If the tool demonstrates acceptable accuracy and referral completion, the application will be released as an open-source module for other pharmacy networks. If it does not, the negative result will be published with the same rigor as a positive one. My track record includes a pre-registered replication study that found topological features do not predict hERG cardiotoxicity, a result I reported directly rather than reframing. This study will follow the same standard. ESSAY: LOCAL RELEVANCE AND IMPLEMENTATION FEASIBILITY Nigeria has approximately 15,000 registered community pharmacists, concentrated in urban and peri-urban areas. These pharmacists are licensed by the Pharmacists Council of Nigeria and operate under the supervision of the Federal Ministry of Health. They are legally permitted to screen, counsel, and refer patients, and they already manage a substantial volume of menstrual-related complaints. The Synthcare platform currently operates a pharmacist-led e-pharmacy model across multiple Nigerian states, with an existing partner network that includes community pharmacies in Oyo and Lagos. This is the implementation base for the proposed study. The study is designed for the regulatory and logistical realities of Nigerian pharmacy practice. The screening tool runs on a standard Android smartphone, which every participating pharmacist already owns. The pictorial blood loss assessment chart requires no equipment beyond the printed chart. The hemoglobin color scale requires a single lancet and a printed color card, both available locally for less than one US dollar per test. Data transmission uses standard mobile networks. No cold chain, no laboratory infrastructure, and no specialist personnel are required at the point of screening. Referral pathways will be established with two tertiary hospitals in Ibadan and Lagos, plus four secondary-level facilities. Each facility has agreed in principle to receive referred patients through a dedicated clinic day. The research coordinator will maintain a referral log and track outcomes through phone follow-up. This design addresses the most common failure point in Nigerian referral systems: the absence of a structured handoff and follow-up mechanism. The study population reflects the programme's requirement that beneficiaries be from Sub-Saharan Africa. All participants will be Nigerian women accessing care through the existing pharmacy system. The intervention is designed to be scalable beyond the study sites. If the tool demonstrates acceptable accuracy and referral completion, the module can be deployed across the full Synthcare pharmacy network and offered to other pharmacy chains under an open license. The cost per screening episode, estimated at under two US dollars, is within the range that Nigerian health insurance schemes and state health programs can absorb. The principal implementation risk is pharmacist attrition and inconsistent protocol adherence. This is mitigated by the two-day training workshop, monthly supervisory visits, and a performance-based incentive of 50 US dollars per pharmacist per quarter. A second risk is low referral completion due to patient cost or distance. This is mitigated by the structured referral note, the dedicated clinic day, and phone follow-up. A third risk is the accuracy of the pictorial blood loss assessment chart in a population with variable pad quality and availability. This is mitigated by the inclusion of the hemoglobin color scale as an independent objective measure. The study is feasible within the proposed 24-month timeline. Ethics approval in Nigeria typically requires 8 to 12 weeks. Tool development and pharmacist training require 16 weeks. Enrollment of 2,000 women across 40 pharmacies at an average of 50 women per pharmacy over 16 months is achievable based on current pharmacy foot traffic data from the Synthcare platform. The study team includes the applicant as principal investigator, a Nigerian research coordinator with pharmacy background, and a gynecologist advisor from the University College Hospital Ibadan. External advisory input is available from the applicant's existing collaborators in computational neuroscience and decision science. CHECKLIST - [ ] Confirm programme deadline on the Grand Challenges website - [ ] Verify eligibility as an independent researcher with Nigerian affiliation - [ ] Confirm budget ceiling of 150,000 USD and 15 percent indirect cost cap - [ ] Draft full proposal narrative using the research statement as core text - [ ] Prepare detailed budget table with line items for personnel, training, data, and dissemination - [ ] Obtain letter of support from Synthcare confirming access to pharmacy network - [ ] Obtain letter of support from University College Hospital Ibadan confirming referral pathway - [ ] Obtain letter of support from a Nigerian academic institution for institutional affiliation - [ ] Prepare CV in the programme's required format - [ ] Prepare biosketch for research coordinator and gynecologist advisor - [ ] Draft data management and sharing plan - [ ] Draft ethics approval plan with timeline for University of Ibadan and Oyo State committees - [ ] Prepare the screening questionnaire and pictorial blood loss assessment chart as appendices - [ ] Verify the WHO hemoglobin color scale is available for procurement in Nigeria - [ ] Confirm the programme's application portal and required file formats - [ ] Submit application before the deadline EDITOR NOTES - Eligibility risk: the applicant is an independent researcher, not affiliated with a Nigerian academic institution. The programme is open to international organizations and LMIC institutions, but a Nigerian institutional co-applicant or host may be required. The letter of support from a Nigerian academic institution is essential and must be secured before submission. - The proposed work is an extension of the Synthcare platform, which is a commercial e-pharmacy venture. The application must clearly state that the HMB screening module does not yet exist, has no revenue, and is a research intervention, not a product launch. The profile explicitly warns against claiming validated IP or product-market fit. - The applicant's research background is in computational neuroscience and protein ML, not clinical gynecology or implementation science. The proposal must emphasize the implementation research design and the role of the gynecologist advisor to compensate for this gap. The applicant should not present himself as a clinical HMB expert. - The pictorial blood loss assessment chart score threshold of 100 and the NICE and FIGO references must be verified against current guidelines before submission. The applicant should confirm the exact threshold used in the reference standard. - The budget figure of 120,000 USD is an estimate. The applicant must build a detailed budget table and confirm it is within the programme's stated ceiling. The 15 percent indirect cost cap must be applied correctly. - The applicant's M.Sc. enrollment at Hasso Plattner Institute begins in Winter Semester 2026/27. The application should clarify how study responsibilities in Nigeria will be managed alongside the degree program, or whether the study timeline accommodates the applicant's relocation to Germany. This is a feasibility question the reviewers will ask.